MedTrace Logo

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)

NCT06002659 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-05-09

No results posted yet for this study

Summary

The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.

Conditions

Interventions

BIOLOGICAL

CAR20(NAP)-T

Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP

DRUG

Cyclophosphamide

pre-conditioning chemotherapy

DRUG

Fludarabine

pre-conditioning chemotherapy

Sponsors & Collaborators

  • Elicera Therapeutics

    collaborator UNKNOWN

  • Uppsala University Hospital

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • Uppsala University

    lead OTHER

Principal Investigators

  • Di Yu, PhD · Uppsala University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2027-12-30
Completion
2027-12-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06002659 on ClinicalTrials.gov